Close Menu

NEW YORK – Biocept said on Tuesday that it has been awarded the CE-IVD mark for its Target Selector EGFR mutation detection assay, allowing the company to commercialize the kits throughout the European Union and other CE mark geographies.

Biocept's Target Selector technology is designed to support individual mutation assays targeting key oncogene mutations. It uses a patented "switch-blocker" method to enrich a specimen for mutations of interest, increasing sensitivity and specificity.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.